Mark Fletcher very well knows this, and to say the Shreya/Recosulin project is "slow" is disingenuous at best and just another example of why long-term GNBT investors have difficulty believing anything he says. Time for a change at the top of Generex.
Nonetheless, the buccal absorption of medications platform (Rapid Mist) is legitimate, and GNBT holds extensive international IP rights. All current hopes lie with the insulin formulation enhancement project at the Center for Molecular Design and Preformulations at he University Health Network (Toronto) and the recently announced collaborations for cannabis with Smoofi and CannScience Innovations.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
